Cargando…

P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY

Detalles Bibliográficos
Autores principales:	Matasar, M., Bartlett, N. L., Sehn, L. H., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L. J., Wei, M. C., Yin, S., To, I., Turner, D., Huang, H., Min, J., Penuel, E., Budde, L. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430131/ http://dx.doi.org/10.1097/01.HS9.0000847372.57687.d4

Ejemplares similares

P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY
por: Sehn, Laurie H., et al.
Publicado: (2023)

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Bartlett, Nancy L., et al.
Publicado: (2023)

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
por: Budde, Lihua E., et al.
Publicado: (2022)

P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
por: Cheah, C. Y., et al.
Publicado: (2022)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
por: Cao, Yang, et al.
Publicado: (2023)

$\beta^{-}$ decay of $^{65}$Mn to $^{65}$Fe
por: Olaizola, B., et al.
Publicado: (2013)

1126. Variability in Antibiotic Use in Children’s Hospitals in the United States
por: Griffith, Hannah, et al.
Publicado: (2019)

1126. Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration
por: Carroll, Ryan, et al.
Publicado: (2018)

1126. Learner Driven Call Center to increase Convalescent Plasma Donation in COVID-19
por: Joyner, Nancy M, et al.
Publicado: (2020)

MAP65/Ase1 promote microtubule flexibility
por: Portran, D., et al.
Publicado: (2013)

SPSC Meeting 65
por: Dainton, J B, et al.
Publicado: (2003)

Cohort Profile: The Lausanne cohort 65+ (Lc65+)
por: Henchoz, Yves, et al.
Publicado: (2021)

Hypercapnic ventilatory response in mice lacking the 65 kDa isoform of Glutamic Acid Decarboxylase (GAD65)
por: Bissonnette, John M, et al.
Publicado: (2004)

The Magnetic Model of the LHC at 6.5 TeV
por: Todesco, E, et al.
Publicado: (2016)

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years
por: Boustani, M. A., et al.
Publicado: (2016)

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
por: Olszewski, Adam J., et al.
Publicado: (2023)

At SC65
por: CERN PhotoLab
Publicado: (1979)

Klaus Winter's 65th Birthday
por: Llewellyn Smith, Christopher Hubert, et al.
Publicado: (1995)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

Proposal: Progress report of SC 65
por: Karlsson, G, et al.
Publicado: (1977)

Giant Cell Tumor of the Tendon Sheath: Experience With 65 Cases
por: Adams, Erin L., et al.
Publicado: (2012)

Comparison of CURB-65 and CRB-65 as predictors of death in community-acquired pneumonia in adults admitted to an ICU
por: Santana, AR, et al.
Publicado: (2013)

Minutes of the 65th LHCC meeting
por: Tsesmelis, E, et al.
Publicado: (2003)

Management Meeting No. 65
por: Reich, K H
Publicado: (1961)

Cases 27–65
por: Ahmad, Jawad
Publicado: (2010)

Census Bulletin No. 65
Publicado: (1881)

Fe65-PTB2 Dimerization Mimics Fe65-APP Interaction
por: Feilen, Lukas P., et al.
Publicado: (2017)

DELPHI Background Measurements at 65 GeV
por: Benvenuti, A C, et al.
Publicado: (1996)

Observations of Background at 65 GeV. MD 22 November 1995
por: Lutters, G, et al.
Publicado: (1996)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Begin risk assessment for falls in women at 45, not 65
por: Harmon, Katherine J, et al.
Publicado: (2019)

Clinical spectrum of high-titre GAD65 antibodies
por: Budhram, Adrian, et al.
Publicado: (2021)

Pion Absorption on $^{3}He$ at 65 MeV
por: Aniol, K A, et al.
Publicado: (1984)

BLMs and thresholds at 6.5/7 TeV
por: Sapinski, M, et al.
Publicado: (2014)

A Machine-Learning Approach for Estimating Subgroup- and Individual-Level Treatment Effects: An Illustration Using the 65 Trial
por: Sadique, Zia, et al.
Publicado: (2022)

Identification of Tropoelastin as a Ligand for the 65-kD FK506-binding Protein, FKBP65, in the Secretory Pathway
por: Davis, Elaine C., et al.
Publicado: (1998)

Characterization and Verification Environment for the RD53A Pixel Readout Chip in 65 nm CMOS
por: Vogt, M., et al.
Publicado: (2017)

Perspectives of 65 nm CMOS technologies for high performance front-end electronics
por: Traversi, G, et al.
Publicado: (2014)

Treatment of Anti-GAD65 Autoimmune Encephalitis With Methylprednisolone
por: Azizi, Shayan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_frgcd0lr864g9has4ft9eovnfk